ArticleJournal of translational medicine2025
Antiphospholipid antibodies inhibit the migration and invasion of trophoblast cells by suppressing the JNK/C-Jun/MMP1 signaling pathway.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Integrated experimental and network pharmacology analyses reveal inhibitory effects of albiflorin on renal cell carcinoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- COLEC12 promotes pancreatic cancer progression via the activation of the TGF-β signaling pathway.Molecular and cellular biochemistry · 2026Article
- Paeoniflorin's role in inhibiting malignant metastasis of gastrointestinal stromal tumors via CYP3A4 modulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- KIF7 promotes the proliferation of clear cell renal cell carcinoma by activating the WNT/β-catenin signaling pathway.Clinical and experimental medicine · 2026Article
- A fatty acid metabolism-based deep learning model predicts biochemical recurrence and identifies NUDT19 as a candidate metabolic factor in prostate cancer.World journal of surgical oncology · 2026Article
- Expression of PIEZO1 in lung adenocarcinoma correlates with PD-L1 expression, cell migration, and poor prognosis: an exploratory study.Discover oncology · 2026Article
- Identification of serum 5'tRF-Val as a promising non-invasive biomarker for early detection of esophageal cancer.Scientific reports · 2026Article
- Construction of a risk scoring model based on machine learning and validation of the role of the key gene SERPINE1 in the progression of colon cancer.Cancer cell international · 2026Article
- Overexpression of MFAP4 inhibits the proliferation, migration, and invasion of bladder cancer cells.Discover oncology · 2026Article
- RGS19 drives tumor progression and immunosuppression in clear cell renal cell carcinoma by modulating CAMs and EMT.World journal of surgical oncology · 2026Article
- The B7 family subgroup reflects tumor cell heterogeneity and patient post-operative prognosis in gallbladder cancer.Biology direct · 2026Article
- Article
- Unraveling the oncogenic and immunomodulatory roles of GINS1: a systematic pan-cancer study.Cancer cell international · 2026Article
- Multi-omics insights into immune tolerance at the maternal-fetal interface in recurrent pregnancy loss: mechanisms, integration challenges, and translational perspectives.Frontiers in immunology · 2026Review
- Integrative analysis of hub genes for recurrent pregnancy loss with antiphospholipid syndrome: integrated bioinformatics analysis, machine learning and experimental validation.Frontiers in immunology · 2026Article
Corrections and comments
- Retracted
Authors and funding
15 authors.
Funding
Abstract
backgroundAntiphospholipid syndrome (APS) is an autoimmune disease primarily manifested by recurrent thrombosis and pregnancy-related complications. The migration and invasion abilities of trophoblast cells play a crucial role in maintaining normal pregnancy. It is now increasingly recognized that adverse pregnancy outcomes in APS are associated with the disruption of trophoblast function by aPL (antiphospholipid antibodies), rather than thrombotic occlusion of the placental vasculature. Therefore, this article aimed to explore the potential mechanisms by which aPL affect trophoblast cell function.
methodAn APS cell model was established in the HTR-8 trophoblast cell line, followed by RNA sequencing to identify key genes involved in trophoblast cell function. To explore the underlying mechanisms, we employed quantitative real-time PCR, Western blotting, immunohistochemistry, ELISA, plasmid transfection and KEGG pathway enrichment analysis. Functional assays, including migration and invasion tests, were conducted to evaluate trophoblast cell ability. Clinical samples were collected, and the expression levels of target molecules in serum were quantified using ELISA. Additionally, an APS animal pregnancy model was developed to assess pregnancy loss rates and analyze the expression of specific target genes in the placenta.
resultsSequencing analysis revealed significant downregulation of MMP1 in the APS model, confirmed by qPCR and Western blotting. Correspondingly, migration and invasion of HTR-8 cells were impaired in the APS group, but MMP1 overexpression restored trophoblast cell function. Serum MMP1 levels were lower in APS patients than in controls. In the animal pregnancy model, the APS group exhibited higher pregnancy loss, with placental immunohistochemistry confirming decreased MMP1 expression. KEGG enrichment analysis of differentially expressed genes between the NC and APS groups revealed a significant difference in the MAPK pathway, with P-JNK showing the most notable reduction. C-Jun, a downstream regulator of JNK, also decreased and modulated MMP1 expression. Notably, Anisomycin treatment increased P-C-Jun, upregulated MMP1, and enhanced trophoblast migration and invasion.
conclusionAPL downregulated MMP1 expression by suppressing the JNK/C-Jun signaling pathway in trophoblast cells, thereby reducing their migratory and invasive capabilities. This represent a potential pathogenic mechanism contributing to adverse pregnancy outcomes in APS patients, highlighting possible therapeutic targets for intervention in APS management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.